e& เผยผลประกอบการประจำไตรมาส 3 ปี 2567 รายรับรวมเติบโต 10% อยู่ที่ 1.44 หมื่นล้านดีแรห์มby October 31, 2024PR Newswire
Astronergy เรียกร้องให้มีการลงมือเพื่ออนาคตยั่งยืนด้วยแคมเปญ “Solar Together, For A Green World”by October 31, 2024PR Newswire
Taiwan’s Fintech Shines in Singapore! FinTechSpace Once Again Leads a Delegation to 2024 Singapore FinTech Festivalby October 31, 2024PR Newswire
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)by October 31, 2024PR Newswire
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UKby October 31, 2024PR Newswire
EQT Acquires Leading SaaS Talent Solutions Provider PageUp to Accelerate Global Expansion and Product Innovationby October 31, 2024PR Newswire
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patientsby October 31, 2024PR Newswire
Toshiba and Naturenix Launch Demonstration Test of Battery Subscription Service for Electric Motorcycle Taxis in Bangkokby October 31, 2024PR Newswire
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLCby October 31, 2024PR Newswire
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLCby October 31, 2024PR Newswire
AIKO Showcases its High-Efficiency N-type ABC Modules at All Energy Australiaby October 31, 2024PR Newswire
MGI’s DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024by October 31, 2024PR Newswire
Nagarro ประกาศซื้อกิจการ FWD View Limited มุ่งยกระดับการดำเนินงานในสหราชอาณาจักรby October 31, 2024PR Newswire
TIER IV’s AI Pilot system certified for Level 4 autonomous bus service in Nagano Prefectureby October 31, 2024PR Newswire
Abionic’s CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaborationby October 31, 2024PR Newswire
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumabby October 31, 2024PR Newswire
